Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Trigeminal neuralgia surgical options

Essential points for quick revision.

Saved on this device
!
Pain crisis can threaten hydration and nutrition

Repeated electric-shock facial pain can make speaking, drinking, eating or oral hygiene impossible; dehydration, weight loss, medication toxicity and suicidal distress need urgent assessment even though trigeminal neuralgia is not usually a neurosurgical emergency.

Action: Assess hydration, nutrition, mental state, sodium, blood count and medicine toxicity; urgently involve neurology or specialist pain services for rescue treatment, and escalate atypical neurological signs or acute eye/oral disease through the relevant emergency pathway.

Synopsis

Confirm a trigeminal-neuralgia phenotype, identify secondary disease and neurovascular compression, and compare microvascular decompression, percutaneous neuroablative procedures and stereotactic radiosurgery through patient-specific trade-offs.

  • Classical trigeminal neuralgia causes recurrent unilateral, brief electric-shock-like pain in one or more trigeminal divisions, triggered by innocuous stimuli; a continuous background component can coexist.
  • MRI is used to exclude secondary disease and characterise neurovascular contact. Contact alone does not prove the diagnosis; morphological nerve change makes symptomatic compression more convincing.
  • Carbamazepine or oxcarbazepine is first-line long-term treatment. Offer surgical discussion when pain is inadequately controlled or effective medicine is poorly tolerated; referral need not wait for years of escalating toxicity.

Key red flags

Objective facial sensory loss, corneal-reflex change, motor weakness, hearing change or other cranial-nerve signs suggest secondary trigeminal neuropathy or a structural lesion.

Bilateral symptoms, young age, long-lasting continuous pain without paroxysms or other neurological features raise multiple sclerosis, tumour and alternative diagnoses.

Visual loss, red painful eye, vesicular rash, fever, facial swelling, dental sepsis or temporal-artery symptoms follow their own urgent pathways.

Inability to drink or eat, marked weight loss, dehydration, hyponatraemia, marrow toxicity or severe drug reaction requires urgent medical care.

New numbness after an ablative procedure can be expected, but painful anaesthesia, corneal hypoesthesia, keratitis or new motor deficit needs urgent specialist review.

Severe depression or suicidal thoughts related to uncontrolled pain require immediate mental-health and safety intervention.

Secondary features

Sensory loss, bilateral pain, other cranial-nerve findings, young onset or demyelinating symptoms increase suspicion for multiple sclerosis, tumour or neuropathy.

Medical-treatment threshold

Inadequate pain control, intolerable adverse effects or dangerous inability to eat/drink justifies specialist escalation and surgical discussion rather than endless dose escalation.

Post-procedure sensory harm

Expected numbness must be distinguished from painful anaesthesia, corneal hypoesthesia/keratitis and new motor or cranial-nerve deficit requiring urgent review.

Reasoning priorities

01
High-resolution MRI brain and trigeminal nerves

Exclude tumour, demyelination and other secondary causes and assess neurovascular compression for surgical planning.

Neurovascular contact alone is common and does not confirm TN. Morphological nerve change and clinical concordance strengthen its relevance to MVD.

Worked reasoning

Worked case: classical TNRefractory pain with concordant vascular compression

A fit adult has typical unilateral triggerable electric-shock pain, medication intolerance and MRI showing concordant neurovascular compression with nerve distortion.

  1. Confirm the classical TN phenotype, exclude dental and secondary mimics, document facial/corneal function and review the high-resolution MRI with a specialist.
  2. Offer neurosurgical discussion because pain is not acceptably controlled or medicines are not tolerated; explain that imaging supports selection but does not make the diagnosis alone.
  3. Discuss MVD as first-line surgery for suitable classical TN because it addresses compression without intentional nerve injury and usually offers the most durable pain freedom.
  4. Compare craniotomy, anaesthetic, hearing, CSF-leak, cranial-nerve, stroke and rare mortality risks with percutaneous numbness/recurrence and radiosurgical delay/numbness.
  5. Choose through shared decision-making and maintain a plan for medicine taper, recurrence, sensory complications and follow-up after the selected procedure.

Key medicines

CarbamazepineInitiate and titrate using the current local formulary and specialist plan rather than a universal schedule.Review interactions, sodium, full blood count, liver function, rash and pregnancy potential; HLA testing is ancestry- and product-guidance-specific. Abrupt unsupervised withdrawal and endless escalation despite toxicity are unsafe.
OxcarbazepineInitiate and titrate using the current local formulary and specialist plan rather than a universal schedule.Hyponatraemia, dizziness, sedation, rash, interactions and pregnancy potential require review. Cross-sensitivity with carbamazepine can occur, and dose conversion is not one-to-one.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

  • Royal College of Surgeons trigeminal neuralgia guidelineFaculty of Dental Surgery multidisciplinary UK guideline published 2021; diagnosis, MRI, medical treatment, surgical referral and procedure-comparison sections read 13 September 2026. Supports phenotype-led diagnosis, timely referral and MVD/percutaneous/radiosurgery trade-offs; evidence quality and local availability vary.
  • European Academy of Neurology TN guidelinePublished 2019; full diagnostic, imaging, medical and surgical recommendation body read 13 September 2026. Supports MRI for secondary causes, neurovascular contact as non-diagnostic, carbamazepine/oxcarbazepine first choice, surgery for inadequate control/intolerance and MVD first-line surgery in classical TN.
  • EAN trigeminal neuralgia systematic reviewPublished 2025; invasive-treatment evidence synthesis and recommendations read 13 September 2026. Supports MVD and radiofrequency as preferred invasive options while grading comparative evidence very low; does not establish a universal procedure hierarchy for every patient.
Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom